Tranexamic acid needs a make over
3 min read
Why can a cheap, straightforward treatment struggle for attention alongside more dramatic interventions? Reflecting on tranexamic acid after CRASH-2 in 2012, Simon Carley questions the appeal of expensive or technically demanding therapies and asks how clinicians can close the gap between evidence and routine practice.